Rye Brook, NY (April 5, 2017) - The Leukemia & Lymphoma Society (LLS) continues to advance the promising field of immunotherapy research, harnessing the body’s own immune system to fight cancer, with a $4 million funding commitment in an investigational therapy being developed by Forty Seven Inc. for lymphoma patients. There are approximately 630,000 patients in the United States living with non-Hodgkin lymp...
Washington, D.C. and Rye Brook, NY (March 23, 2017) –The Leukemia & Lymphoma Society (LLS) together with the National Black Church Initiative (NBCI) announce the launch of a church-based initiative addressing striking health disparities among African Americans with multiple myeloma. Black Americans have twice the incidence of multiple myeloma as white Americans, and recent studies show black Americans are signi...
March 22, 2017 (Rye Brook, NY) – As the world’s leading non-profit dedicated to fighting blood cancers, The Leukemia & Lymphoma Society (LLS) has played a role in most therapies used today to treat blood cancer patients, some of which are even helping patients with other cancers and serious diseases. Such advances are possible due to LLS’s significant investment in cutting-edge research – more t...
The Leukemia & Lymphoma Society (LLS) firmly opposes the Administration’s proposed budget, which reduces the funding for the National Institutes of Health (NIH) by $5.8 billion. These cuts risk derailing decades of advancement in the diagnosis, understanding and treatment of deadly blood cancers. LLS is calling upon members of Congress to reject these proposed cuts and increase funding for the NIH in future app...
Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday: